Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2013

View Archived Issues

Serum IL-33 levels predict rheumatoid arthritis response to rituximab

MOD-6030 shows promise in animal models of obesity and type 2 diabetes

Uncovering new genetic and clinical biomarkers of human disease

Vaxart reports preclinical findings for new H7N9 avian influenza vaccine

ViroPharma provides update on phase II studies of maribavir

EntreMed files new drug global trial application for ENMD-2076 in China

Navidea Biopharmaceuticals begins phase III NAV-4694 trial

Boehringer Ingelheim synthesizes new GPR119 receptor agonists

AstraZeneca acquires Pearl Therapeutics

Verastem completes first stage of VS-6063 combination trial

FDA approves Exelon patch to treat all stages of Alzheimer's disease

Bisono Tape transdermal patch approved in Japan

Soliris receives FDA orphan drug designation for neuromyelitis optica

Drisapersen receives FDA breakthrough therapy designation

UGP-302 evaluated in animal models of obesity and diabetes

Amgen presents novel tankyrase inhibitor

Approval of Lemtrada for relapsing remitting MS recommended in Europe

Nexavar submitted in U.S and E.U. for radioactive iodine-refractory differentiated thyroid cancer

EMA recommends approval of two GSK cancer drugs

European CHMP recommends approval of two infliximab biosimilars

Takeda withdraws MAA for peginesatide in Europe

FDA issues complete response for Xarelto to reduce the risk of stent thrombosis in ACS

Regorafenib recommended for approval in the E.U.

CHMP issues positive opinion on two variations for Velcade

Autifony Therapeutics presents new potassium channel modulators

Merck & Co. receives FDA complete response letter for suvorexant

Cadila Healthcare synthesizes novel renin inhibitors